Our Products
Learn more about MPap and RitaPa
The MPap test uses a methylation-specific qPCR technology for the qualitative detection of methylation status of specific genes from samples collected through non-invasive cervical scraping. The test results act as a reference point to help medical practitioners determine whether a woman aged 40 or above suffering from abnormal uterine bleeding is susceptible to endometrial cancer. The results also help medical practitioners decide whether further invasive endometrial sampling is necessary before performing the procedure.
Like the MPap test, the RitaPap test also uses a methylation-specific qPCR technology for qualitative detection of specific genes’ methylation status, except through an even less invasive sampling collection methodology. Unlike the MPap, the RitaPap test collects samples through tampon use, a common women’s hygiene product.
The MUrine test
The Murine is a kit that uses urine samples to analyze the methylation of specific genes for the screening of urothelial carcinoma or bladder cancer. The test is a reference for clinicians to help determine whether there is further need for more invasive cystoscopy procedures.
AIrMec (In development)
Guzip has other products in research and development.
The Bio AI project is in development and is a personalized healthcare application for women going through menopause.
The Bio AI project is in development and is a personalized healthcare application for women going through menopause.
Why Methylation biomarkers?
Unlike traditional detection techniques, the DNA methylation technology allows for a molecular based detection that allows for a non-invasive collection methodology. Traditionally, cell-based detection techniques meant that cells from the endometrium will need to be gathered for analysis through invasive means. The use of DNA methylation biomarkers allows samples to be safely gathered through non-invasive means.
